iTeos Belgium
ActiveFrom the official registers: KBO 14 annual accounts at the National Bank publications in the Belgian Official Gazette
Summary
The computed 12-month bankruptcy probability of iTeos Belgium is 4.3% (elevated). The 2025 annual accounts show negative equity (-€5.1m) and a net result of -€93.5m. Equity fluctuates too strongly from year to year to read a trend from it. Its solvency ranks better than 10% of 239 sector peers (NACE 72, financial year 2025). The company has been active since 2011 and the Belgian Official Gazette contains no insolvency or warning signals.
Overview
Official details
KBO- Status
- Active since 01-08-2011 Normal situation
- Registered office
- 65 active companies are registered at this address 12 started in the 12 months before. Source: KBO register, as of 1 November 2026.
- Activity
- Research and development on biotechnology NACE 72101
- Establishment units
- 2.201.577.920 6041 Charleroi, since 01-08-2011
- 2.353.232.371 6041 Charleroi, since 18-12-2023
- Financial year end
- 31 December
- Peppol
- Reachable since 09-01-2026
Board and ownership
- DETHEUX Michel Marcel Alfred PierreCEO
- Kevin TangDirector · since 29-08-2025
- Auditor
- Deloitte Bedrijfsrevisoren/Réviseurs d'Entreprises
- iTeos Therapeutics LLC100%annual accounts 2025
Financial position
- Bankruptcy probabilitywithin 12 months
- 4.3%
- Loss
- €93.5m
- Equity
- -€5.1m
- Total assets
- €46.3m
- ▼ 67.4%
- Staff
- 77.5 FTE
- ▼ 39.5%
Score breakdownraises riskLoss of €93.5m (financial year 2025)Negative equity -€5.1mLiquidity: current ratio 0.56, cash €1.5mLast filed accounts filed 45 days late; 1 of the last 3 accounts lateShow the evidence
Checked score
About 4 in 100 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 72, medium-sized). It does better than 13% of them on solvency, 6% on liquidity, 12% on profitability and 17% on growth.
The bankruptcy probability was computed on 31-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 7 accounts on average 43 days before the deadline. In the sector (NACE 72), the median for financial year 2024 was 13 days before the deadline, and 32% of those companies filed late.
Searched, nothing found (2)
Key points
- Risk: Negative equitydebts exceed assets in financial year 2025 -€5.1m View
- Caution: From profit to loss in 2025after a profit of €40.8m in 2024 -€93.5m View
- Caution: Lower net result than 95% of companies in research and developmentsector median €3,198 · 237 companies -€93.5m View
- New directorslatest change 21-05-2026 · 1 in office 5 joined View
Comparable companies
These companies have the same main activity as iTeos Belgium: research and development on biotechnology (NACE 72101). They are comparable in size and age: total assets between €16m and €85m, founded between 2013 and 2015.
| Company | Total assets | Turnover |
|---|---|---|
| iTeos Belgium Charleroi | €46.3m | - |
| Confo Therapeutics Gent | €37.8m | €0.2m |
| LaCAR MDx technologies Liège | €29.1m | €8.1m |
| Biotalys Gent | €16.3m | - |
| NOVADIP BIOSCIENCES Mont-Saint-Guibert | €85.3m | - |
| Inbiose Gent | €17.2m | €6.3m |
| Enovalife Evere | €21.9m | €25.2m |
Documents
Annual accounts at the NBB
- Annual accounts 2025filed on 14-09-2026
- Annual accounts 2024filed on 04-06-2025
- Annual accounts 2023filed on 30-05-2024
- Annual accounts 2022filed on 01-06-2023
Acts in the Belgian Official Gazette
- Resignations & appointmentsact of 21-05-2026
- Registered officeact of 21-04-2026
- Resignations & appointmentsact of 24-10-2025
- Resignations & appointmentsact of 16-12-2024
Articles and registers
- Coordinated articles of associationnotaries' database
- Entry in the KBO registerKBO Public Search
Key facts about iTeos Belgium
- What is the company number of iTeos Belgium?
- The company number of iTeos Belgium is 0838.316.659. The VAT number is the same number with BE in front: BE 0838.316.659.
- Where is iTeos Belgium based?
- The registered office is at Rue de Venise 21, 6040 Charleroi.Company details
- What does iTeos Belgium do?
- According to the KBO register, the main activity is research and development on biotechnology (NACE 72101).
- What is the legal form of iTeos Belgium?
- The legal form of iTeos Belgium is Public limited company (NV).
- When was iTeos Belgium founded?
- iTeos Belgium was founded on 01-08-2011.
- Is iTeos Belgium still active?
- Yes, iTeos Belgium is an active enterprise in the KBO register.
- How many employees does iTeos Belgium have?
- iTeos Belgium had an average of 77.5 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- What is the turnover of iTeos Belgium?
- The annual accounts for financial year 2025 state no turnover. In financial year 2024 turnover was €32.5m.
- Is iTeos Belgium profitable?
- In financial year 2025, iTeos Belgium made a loss of €93.5m.
- Where can I find the annual accounts of iTeos Belgium?
- iTeos Belgium filed 14 annual accounts with the National Bank of Belgium, the latest for financial year 2025.Annual accounts at the National Bank
- When are the next annual accounts of iTeos Belgium due?
- iTeos Belgium must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
See how customers, suppliers and banks see your own company and what to improve first.